Condition: Adenoid Cystic Carcinoma · Metastatic Adenoid Cystic Carcinoma · Recurrent Adenoid Cystic Carcinoma · Sponsor: Remix Therapeutics
The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with advanced Adenoid Cystic Carcinoma (ACC)
This description comes directly from the study's public registry record.
Remix Therapeutics · 781-827-0902 · ClinicalTrials@remixtx.com
Rosalie Jiang · 781-584-9390 · rjiang@remixtx.com
Always discuss trial participation with your own doctor first.
| University of California San Francisco Helen Diller Comprehensive Cancer Center | San Francisco, California, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| Dana Farber Cancer Research Institute | Boston, Massachusetts, United States | Recruiting |
| University of Michigan Rogel Cancer Center | Ann Arbor, Michigan, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Sarah Cannon Research Institute | Nashville, Tennessee, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Centre Antoine Lacassagne | Nice, France | Recruiting |
| Institut de Cancerologie Gustave-Roussy | Villejuif, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06118086